Gain Therapeutics GANX 深 沪
已收盘 12-19 16:00:00 美东时间
2.86
+0.610
+27.11%
华盛通- 最 高4.34
- 今 开2.38
- 成交量 1224.91万股
- 最 低 2.14
- 昨 收 2.25
- 总市值 3398.65万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 103.08%
- 52周最低 1.41
- 委 比 17.31%
- 总股本 1188.34万
- 历史最高 17.93
- 量 比 4.83
- 振 幅 97.78%
- 历史最低 0.89
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics to Participate in Upcoming Investor Conferences
Gain Therapeutics' CEO, Gene Mack, will present at the H.C. Wainwright Neuro conference on June 17 and the BIO 2025 conference on June 18. Gain develops next-generation allosteric therapies targeting neurodegenerative diseases and rare genetic disorders. Investors can contact the company for meetings.
06-10 12:00
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
Gain Therapeutics将参加2025年6月5日至7日在蒙特利尔举行的GBA1会议，并于6月5日晚11:20 EST进行口头报告，讨论其下一代变构小分子疗法，包括治疗帕金森病及其他疾病。公司还利用Magellan平台加速疾病改善治疗药物的研发。如需更多信息，请联系投资人关系或媒体联系人。
05-29 12:45
Scotiabank Initiates Coverage On Gain Therapeutics with Sector Outperform Rating, Announces Price Target of $12
Scotiabank analyst Louise Chen initiates coverage on Gain Therapeutics (NASDAQ:GANX) with a Sector Outperform rating and announces Price Target of $12.
03-08 06:49
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
2024-09-03 19:32
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Thursday, Gain Therapeutics, Inc. (NASDAQ:GANX) released results from the Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of GT-02287. The company previously announced that no discontinuations or serious adverse events were reported when the study concluded. Also Read: EXCLU...
2024-08-30 00:05
Gain Therapeutics Says Phase 1 Data Confirm Safety of Parkinson's Disease Drug Candidate
08:48 AM EDT, 08/29/2024 (MT Newswires) -- Gain Therapeutics (GANX) said Thursday that a review of unblinded data from a phase 1 study of GT-02287 to treat Parkinson's disease confirmed that the drug candidate is safe and generally well tolerated. The company said it expects to begin the phase 1b st...
2024-08-29 20:48
